| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| PAR Pharmaceutical has a current Overall Rating of B (Positive). | 7 |
$25 |
| 29-Nov-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (PRX). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (PRX). | 5 |
$18 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| S&P Small Cap Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$40 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| S&P Super 1500 Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$40 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | PHARMACEUTICAL RESOURCES INC (PRX=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | PHARMACEUTICAL RESOURCES INC (PRX=US) 12-months forecast | 1 |
$15 |
| 27-Nov-2009 | Validea |
N/A
| Validea Guru Analysis Report for PRX. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others. | 0 |
$18 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Comprehensive Rating Report | 48 |
$99 |
1.48% Nasdaq 
Research Reports
